ABOUT US

ESG

Genuone Sciences is building a strategic ESG roadmap as we become a fully trusted company.

We are committed to improving our environmental, social and corporate governance practices as we plan for sustainable growth and gain valuable insights from both short- and long-term operations. We intend to establish eco-friendly policies; earn environmental management certification; practice fair trade that prohibits corrupt activities; promote social contribution programs; expand corporate governance reports and disclosures; and implement transparent and balanced management by establishing and operating committees with specialized missions.

We will preemptively respond to domestic and overseas requirements and outside experts for socially responsible management while strengthening communications with stakeholders.

By upholding ESG principles in our management, we will faithfully fulfill our social responsibilities to the global society while promoting economic, social and environmental values for a better world.

Support for the Task Force on Climate-related Financial Disclosures

Genuone Sciences is pleased to join more than 2,000 organizations around the world in declaring our support for the Financial Stability Board, FSB Task Force on Climate-related Financial Disclosures.

Across the public and private sector, we recognize the importance of increasing transparency of climate-related risks and opportunities, promoting more informed financial decision-making, and building a more resilient financial system.

Facts & Figures

Genuone Sciences is South Korea's leading CDMO pharmaceutical company.
Building on our extensive pharmaceutical development technologies and experience, we offer a full lineup of manufacturing and production facilities as well as comprehensive clinical development capabilities.

One-Stop CDMO Services
Providing formulations development
and analytic services, from small-scale
clinical trials to large-scale commercial supply
80%
Customer percentage of domestic pharmaceutical companies
650numbers
Number of medicines approved by the Korean Ministry of Food and Drug Safety (MFDS)
20types
Number of available
formulations
R&D, Production Infrastructure
1 R&D center, 2 plants
5.5B Units
Total production of synthetic drugs
20countries
Number of export countries
845persons
Number of employees
85persons
Number of R&D professionals
8%
R&D investment-to-sales ratio in past 3 years
ENVIRONMENT
  • Environmental Management Policy
  • E-Observation System
  • Environmental Performance Evaluation System
  • ISO 14001 Acquisition and Eco-Friendly Maintenance
  • Strategies for Reducing Waste Emissions
SOCIAL
  • Stakeholder Safety System
  • Talent Management System
  • Human Rights Management, Diversity and Inclusion Policies
  • Customer Response Principles
  • ISO 37001 and maintain anti-corruption authentication
  • Fair Trade Principles
  • CSR and Partner Management System
GOVERNANCE
  • Board of Directors Risk Management System
  • Audit System : Risk Assessment, Internal Audit
  • Information Disclosure Policy
  • Publication of Sustainability Reports

Genuone Sciences Sustainability Report

top
0%/progress>